{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:10:27Z","timestamp":1788786627080,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Autoimmune and inflammatory diseases are characterized by complex pathophysiological mechanisms that promote systemic inflammation and multi-organ involvement [...]<\/jats:p>","DOI":"10.3390\/jcm15176914","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:12:25Z","timestamp":1788783145000},"page":"6914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Risks in Autoimmune and Inflammatory Diseases"],"prefix":"10.3390","volume":"15","author":[{"given":"Elena","family":"Rezus","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Rehabilitation, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"I Rheumatology Clinic, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-7325","authenticated-orcid":false,"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Rehabilitation, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 1 Independence Boulevard, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mercader-Salvans, J., Garc\u00eda-Gonz\u00e1lez, M., G\u00f3mez-Bernal, F., Quevedo-Abeledo, J.C., de Vera-Gonz\u00e1lez, A., Gonz\u00e1lez-Delgado, A., L\u00f3pez-Mej\u00edas, R., Mart\u00edn-Gonz\u00e1lez, C., Gonz\u00e1lez-Gay, M.A., and Ferraz-Amaro, I. (2023). Relationship between Disease Characteristics and Circulating Interleukin 6 in a Well-Characterized Cohort of Patients with Systemic Lupus Erythematosus. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814006"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/art.43097","article-title":"Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients with Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission","volume":"77","author":"Papazoglou","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s10067-023-06608-6","article-title":"Risk Factors for Cardiovascular Diseases in Patients with Systemic Lupus Erythematosus: An Umbrella Review","volume":"42","author":"Katayama","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11883-023-01149-4","article-title":"Atherosclerosis in Systemic Lupus Erythematosus","volume":"25","author":"Tobin","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/joim.13557","article-title":"Systemic Lupus Erythematosus and Cardiovascular Disease","volume":"293","author":"Frostegrd","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rdc.2022.02.003","article-title":"Managing Cardiovascular Risk in Patients with Rheumatic Disease","volume":"48","author":"Ferguson","year":"2022","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR Recommendations for Cardiovascular Risk Management in Rheumatic and Musculoskeletal Diseases, Including Systemic Lupus Erythematosus and Antiphospholipid Syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12265-026-10753-z","article-title":"Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-Associated Cardiovascular Disease and Neuropsychiatric Manifestations","volume":"19","author":"Butler","year":"2026","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"152468","DOI":"10.1016\/j.semarthrit.2024.152468","article-title":"Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus","volume":"67","author":"Choi","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/ecr.2020.44","article-title":"Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment","volume":"16","author":"Kerola","year":"2021","journal-title":"Eur. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of Risk Factors Associated with Cardiovascular Outcomes in Patients with Rheumatoid Arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic Review and Meta-Analysis of Cardiovascular Risk in Rheumatological Disease: Symptomatic and Non-Symptomatic Events in Rheumatoid Arthritis and Systemic Lupus Erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hedar, A.M., Stradner, M.H., Roessler, A., and Goswami, N. (2021). Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194427"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.12688\/f1000research.112921.2","article-title":"Accelerated Atherosclerosis in Rheumatoid Arthritis: A Systematic Review","volume":"11","author":"Raj","year":"2023","journal-title":"F1000Research"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dijkshoorn, B., Raadsen, R., and Nurmohamed, M.T. (2022). Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102704"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Charca, L.C., Loredo, M., Pardo, E., Bra\u00f1a, I., Burger, S., Alvarez, P., and Queiro, R. (2026). Serum Urate as a Cardiometabolic Risk Enhancer Beyond SCORE2 in Psoriatic Arthritis. J. Clin. Med., 15.","DOI":"10.3390\/jcm15155788"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Richter, P., Rezus, C., Adam, C.A., Mihai, I.R., Burlui, A.M., and Rezus, E. (2026). IL-6 in Systemic Lupus Erythematosus: At the Intersection of Disease Activity and Cardiovascular Risk. J. Clin. Med., 15.","DOI":"10.3390\/jcm15135243"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Deseatnicova, E., Nistor, A., Tigulea, A., Grosu, M., Dodu, S., Russu, E., Andries, L., and Groppa, L. (2026). Carotid Atherosclerosis and T-Cell Imbalance in Women with Rheumatoid Arthritis: A Cross-Sectional Study of Intima-Media Thickness, Anti-CCP Antibodies and CD4\/CD8 Ratio. J. Clin. Med., 15.","DOI":"10.3390\/jcm15135054"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Di Lisi, D., Manno, G., Madaudo, C., Perone, F., Leonforte, F., Parlati, A.L.M., Flex, A., Novo, S., Tondi, P., and Galassi, A.R. (2026). Impact of Insulin Resistance and Preclinical Atherosclerosis Parameters in Long-Term Prediction of Cardiovascular Events: A Seven-Year Prospective Study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020808"},{"key":"ref_20","first-page":"217","article-title":"Impact of Ankle-Brachial Index Calculations on Peripheral Arterial Disease Prevalence and as a Predictor of Cardiovascular Risk","volume":"62","author":"Sartipy","year":"2022","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/00033197241226512","article-title":"Ankle-Brachial Index: Diagnostic Tool of Peripheral Arterial Disease and Predictor of Cardiovascular Risk\u2014An Update of Current Knowledge","volume":"76","author":"Poredos","year":"2024","journal-title":"Angiology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rojas-Gimenez, M., Lopez-Medina, C., Calvo-Gutierrez, J., Puche-Larrubia, M.A., Gomez-Garcia, I., Segui-Azpilcueta, P., Abalos-Aguilera, M.C., Ruiz, D., Collantes-Estevez, E., and Escudero-Contreras, A. (2022). Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010064"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kaymaz-Tahra, S., Ozguven, S., Avcu, A., Filizoglu, N., Unal, A.U., Ones, T., Erdil, T.Y., Alibaz-Oner, F., and Direskeneli, H. (2025). Involvement of Iliofemoral Arteries in PET\/CT Is Associated with Atherosclerotic Risk Factors in Takayasu\u2019s Arteritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14238607"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Duman, H., Durak, H., C\u00fcre, O., \u00c7etin, M., \u00d6zy\u0131ld\u0131z, A.G., Erg\u00fcl, E., \u015eahin, M.A., \u00d6zsipahi, A., Tuncer, A.Y., and Dindar, B. (2025). Impact of Colchicine Therapy on Ventriculoarterial Coupling in Familial Mediterranean Fever: A Cross-Sectional Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14196902"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Popescu, D., Badescu, M.C., Rezus, E., Tanase, D.M., Ouatu, A., Dima, N., Buliga-Finis, O.-N., Gosav, E.M., and Rezus, C. (2025). Effects of Janus Kinase Inhibitors on Cardiovascular Risk in Rheumatic Diseases: A Prospective Pilot Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14134676"},{"key":"ref_26","first-page":"119","article-title":"Risk of Major Adverse Cardiovascular Events with Tofacitinib versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis with or without a History of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis from ORAL Surveillance","volume":"81","author":"Buch","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2022 Update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Czkolyov\u00e1, M., Hamar, A., Pusztai, A., Tajti, G., V\u00e9gh, E., Peth\u0151, Z., Bodn\u00e1r, N., Horv\u00e1th, A., S\u00f3s, B., and Szamosi, S. (2022). Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis. Biomolecules, 12.","DOI":"10.3390\/biom12101483"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Anyfanti, P., Angeloudi, E., Dara, A., Pagkopoulou, E., Moysidou, G.S., Deuteraiou, K., Boutel, M., Bekiari, E., Doumas, M., and Kitas, G.D. (2024). Non-Invasive Assessment of Micro- and Macrovascular Function after Initiation of JAK Inhibitors in Patients with Rheumatoid Arthritis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14080834"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Szinay, D., Szab\u00f3, K., Moln\u00e1r, H., B\u00e9ldi, T., Bencs, V., L\u0151rincz, H., Harangi, M., Griger, Z., and Nagy-Vincze, M. (2025). Assessment of Efficacy and Safety of Lipid-Lowering Treatment and Its Importance in Risk Assessment and Prevention in a Hungarian Myositis Cohort. J. Clin. Med., 14.","DOI":"10.20944\/preprints202503.2370.v1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Oiegar, R., and Pop, D. (2025). Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186461"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Staveri, C., Vartela, V., Mavrogeni, S.I., and Liossis, S.C. (2025). Combining Laboratory and Imaging Evaluation for Cardiovascular Risk Stratification in Systemic Lupus Erythematosus. J. Clin. Med., 14.","DOI":"10.3390\/jcm14145085"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:41:55Z","timestamp":1788784915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":32,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176914"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176914","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}